| 2023 |
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? |
Articolo in rivista |
Vai |
| 2023 |
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay |
Articolo in rivista |
Vai |
| 2023 |
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab |
Articolo in rivista |
Vai |
| 2023 |
Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis |
Review essay (rassegna critica) |
Vai |
| 2023 |
The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors |
Articolo in rivista |
Vai |
| 2023 |
The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier? |
Articolo in rivista |
Vai |
| 2023 |
Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD) |
Articolo in rivista |
Vai |
| 2023 |
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study |
Articolo in rivista |
Vai |
| 2023 |
Network approach in liquidomics landscape |
Articolo in rivista |
Vai |
| 2022 |
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible |
Articolo in rivista |
Vai |
| 2022 |
Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis |
Articolo in rivista |
Vai |
| 2022 |
Liquid biopsy: a right tool in a right context? |
Capitolo o Saggio |
Vai |
| 2022 |
Future perspectives |
Capitolo o Saggio |
Vai |
| 2022 |
Current clinically validated applications of liquid biopsy |
Capitolo o Saggio |
Vai |
| 2022 |
Molecular tumor board |
Capitolo o Saggio |
Vai |
| 2022 |
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study |
Articolo in rivista |
Vai |
| 2022 |
Early detection screening: myth or reality? |
Capitolo o Saggio |
Vai |
| 2022 |
Liquid biopsy and immunotherapy: is all that glitter gold? |
Capitolo o Saggio |
Vai |
| 2022 |
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors |
Articolo in rivista |
Vai |
| 2022 |
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis |
Articolo in rivista |
Vai |
| 2022 |
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis |
Articolo in rivista |
Vai |
| 2022 |
PROTACs: The Future of Leukemia Therapeutics |
Articolo in rivista |
Vai |
| 2022 |
Editorial: The Effect of the COVID-19 Pandemic on Cancer Patients and Healthcare |
Lettera |
Vai |
| 2022 |
Accuracy evaluation of orthodontic movements with aligners: a prospective observational study. |
Articolo in rivista |
Vai |
| 2022 |
Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement |
Articolo in rivista |
Vai |
| 2021 |
A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic |
Articolo in rivista |
Vai |
| 2021 |
Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—A trial-level meta-analysis in PD-L1 selected subgroups |
Articolo in rivista |
Vai |
| 2021 |
Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study |
Articolo in rivista |
Vai |
| 2021 |
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies |
Articolo in rivista |
Vai |
| 2021 |
Effects of the number of removed lymph nodes on survival outcome in patients with sentinel node-negative breast cancer |
Articolo in rivista |
Vai |
| 2021 |
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) |
Articolo in rivista |
Vai |
| 2021 |
The treatment of medication-related osteonecrosis of the jaw (Mronj): A systematic review with a pooled analysis of only surgery versus combined protocols |
Review essay (rassegna critica) |
Vai |
| 2021 |
Second medical opinion in oncological setting |
Articolo in rivista |
Vai |
| 2021 |
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials |
Articolo in rivista |
Vai |
| 2021 |
Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma |
Recensione in rivista |
Vai |
| 2021 |
Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses |
Articolo in rivista |
Vai |
| 2020 |
Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis |
Articolo in rivista |
Vai |
| 2020 |
2020 Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials |
Lettera |
Vai |
| 2020 |
COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients? |
Articolo in rivista |
Vai |
| 2020 |
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score |
Articolo in rivista |
Vai |
| 2020 |
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study |
Articolo in rivista |
Vai |
| 2020 |
The emerging therapeutic landscape of alk inhibitors in non-small cell lung cancer |
Review essay (rassegna critica) |
Vai |
| 2020 |
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal |
Articolo in rivista |
Vai |
| 2020 |
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab |
Articolo in rivista |
Vai |
| 2020 |
Impact of BMI on Preoperative Axillary Ultrasound Assessment in Patients With Early Breast Cancer |
Articolo in rivista |
Vai |
| 2019 |
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients |
Articolo in rivista |
Vai |
| 2019 |
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis |
Articolo in rivista |
Vai |
| 2019 |
An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesistargeting TKI-based therapy |
Articolo in rivista |
Vai |
| 2019 |
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials |
Articolo in rivista |
Vai |
| 2019 |
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis |
Articolo in rivista |
Vai |
| 2019 |
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials |
Articolo in rivista |
Vai |
| 2019 |
Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1 |
Articolo in rivista |
Vai |
| 2019 |
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) |
Review essay (rassegna critica) |
Vai |
| 2018 |
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis |
Articolo in rivista |
Vai |
| 2018 |
The use of same in chemotherapy-induced liver injury |
Articolo in rivista |
Vai |
| 2018 |
Dose-finding study of oxaliplatin associated to capecitabinebased preoperative chemoradiotherapy in locally advanced rectal cancer |
Articolo in rivista |
Vai |
| 2018 |
Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer |
Articolo in rivista |
Vai |
| 2018 |
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential |
Articolo in rivista |
Vai |
| 2018 |
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab |
Articolo in rivista |
Vai |
| 2018 |
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis |
Articolo in rivista |
Vai |
| 2018 |
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial |
Articolo in rivista |
Vai |
| 2018 |
Erratum to: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis (Scientific Reports, (2018), 8, 1, (13379), 10.1038/s41598-018-30780-4) |
Nota o commento |
Vai |
| 2018 |
Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: Recommended schedule for expected activity and safety and phase II study |
Articolo in rivista |
Vai |
| 2018 |
Indications for locoregional tumor therapies: CRC liver metastases |
Capitolo o Saggio |
Vai |
| 2017 |
Potential miRNAs involved in molecular pathways mediating the anticancer effects of short term starvation in breast cancer cells treated with doxorubicin |
Abstract in atti di convegno pubblicato in rivista |
Vai |
| 2017 |
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials |
Articolo in rivista |
Vai |
| 2017 |
Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin |
Articolo in rivista |
Vai |
| 2017 |
Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study |
Articolo in rivista |
Vai |
| 2017 |
Impact of phospho-Akt expression on the clinical outcome and activity of gemcitabine and Akt inhibitors in pancreatic ductal adenocarcinoma |
Abstract in atti di convegno pubblicato in rivista |
Vai |
| 2017 |
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors |
Articolo in rivista |
Vai |
| 2017 |
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy |
Articolo in rivista |
Vai |
| 2016 |
Dietary restriction: could it be considered as speed bump on tumor progression road? |
Articolo in rivista |
Vai |
| 2016 |
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis |
Articolo in rivista |
Vai |
| 2016 |
Triple negative breast cancer: Shedding light onto the role of pi3k/akt/mtor pathway |
Review essay (rassegna critica) |
Vai |
| 2016 |
Nintedanib in NSCLC: Evidence to date and place in therapy |
Articolo in rivista |
Vai |
| 2016 |
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus |
Articolo in rivista |
Vai |
| 2016 |
Cardiotoxic Effects of Anti-VEGFR Tyrosine Kinase Inhibitors |
Capitolo o Saggio |
Vai |
| 2016 |
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? |
Articolo in rivista |
Vai |
| 2016 |
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? |
Articolo in rivista |
Vai |
| 2016 |
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis |
Articolo in rivista |
Vai |
| 2015 |
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario |
Articolo in rivista |
Vai |
| 2015 |
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? |
Articolo in rivista |
Vai |
| 2015 |
Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy |
Articolo in rivista |
Vai |
| 2015 |
Clinical efficacy and safety of ezetimibe on major cardiovascular endpoints: Systematic review and meta-analysis of randomized controlled trials |
Articolo in rivista |
Vai |
| 2015 |
Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis |
Articolo in rivista |
Vai |
| 2014 |
Ramucirumab and its use in gastric cancer treatment |
Articolo in rivista |
Vai |
| 2013 |
Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations |
Articolo in rivista |
Vai |
| 2013 |
Monoclonal antibodies in gastrointestinal cancers |
Articolo in rivista |
Vai |
| 2010 |
The use of pegylated liposomal doxorubicin (PLD) in association with weekly paclitaxel as second line therapy in metastatic bladder carcinoma: final results |
eedings |
Vai |
| 2010 |
Combined treatment with fulvestrant plus capecitabine in elderly advanced breast cancer (EABC): Three-year evaluation of efficacy and safety |
eedings |
Vai |
